These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26073353)

  • 1. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
    Soto-Molina H; Pizarro-Castellanos M; Rosado-Pérez J; Rizzoli-Córdoba A; Lara-Padilla E; del Valle-Laisequilla CF; Reyes-García JG
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):541-9. PubMed ID: 26073353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
    Cercato C; Roizenblatt VA; Leança CC; Segal A; Lopes Filho AP; Mancini MC; Halpern A
    Int J Obes (Lond); 2009 Aug; 33(8):857-65. PubMed ID: 19564877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
    Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.
    Kang JG; Park CY; Kang JH; Park YW; Park SW
    Diabetes Obes Metab; 2010 Oct; 12(10):876-82. PubMed ID: 20920040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
    Kim KK; Cho HJ; Kang HC; Youn BB; Lee KR
    Yonsei Med J; 2006 Oct; 47(5):614-25. PubMed ID: 17066505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.
    Astell KJ; Mathai ML; McAinch AJ; Stathis CG; Su XQ
    Complement Ther Med; 2013 Jun; 21(3):180-9. PubMed ID: 23642949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
    Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
    Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.